CA1286991C - Medicament pour le traitement des infections a virus - Google Patents

Medicament pour le traitement des infections a virus

Info

Publication number
CA1286991C
CA1286991C CA000541194A CA541194A CA1286991C CA 1286991 C CA1286991 C CA 1286991C CA 000541194 A CA000541194 A CA 000541194A CA 541194 A CA541194 A CA 541194A CA 1286991 C CA1286991 C CA 1286991C
Authority
CA
Canada
Prior art keywords
deoxy
treatment
fluorothymidine
acceptable salt
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000541194A
Other languages
English (en)
Inventor
Bertil Frank Harald Eriksson
Karl Nils Gunnar Johansson
Goran Bertil Stening
Bo Fredrik Oberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB filed Critical Medivir AB
Application granted granted Critical
Publication of CA1286991C publication Critical patent/CA1286991C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
CA000541194A 1986-07-04 1987-07-03 Medicament pour le traitement des infections a virus Expired - Lifetime CA1286991C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8602981A SE8602981D0 (sv) 1986-07-04 1986-07-04 Novel medicinal use
SE8602981-6 1986-07-04

Publications (1)

Publication Number Publication Date
CA1286991C true CA1286991C (fr) 1991-07-30

Family

ID=20365027

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000541194A Expired - Lifetime CA1286991C (fr) 1986-07-04 1987-07-03 Medicament pour le traitement des infections a virus

Country Status (10)

Country Link
US (1) US6358934B1 (fr)
EP (1) EP0277151B1 (fr)
JP (1) JP2540576B2 (fr)
AT (1) ATE68349T1 (fr)
AU (1) AU598575B2 (fr)
CA (1) CA1286991C (fr)
DE (1) DE3773892D1 (fr)
DK (1) DK172617B1 (fr)
SE (1) SE8602981D0 (fr)
WO (1) WO1988000050A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
SE9800452D0 (sv) * 1998-02-13 1998-02-13 Medivir Ab Antivirals
GB8719877D0 (en) * 1987-08-22 1987-09-30 Wellcome Found Antiviral compounds
US5506215A (en) * 1987-11-03 1996-04-09 Medivir Ab 1-(3'-fluoro-2',3'-dideoxy-β-D-ribofuranosyl)-5-substituted pyrimidine nucleosides
GB8726136D0 (en) * 1987-11-07 1987-12-09 Wellcome Found Therapeutic nucleosides
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
GB8904855D0 (en) * 1989-03-03 1989-04-12 Beecham Group Plc Pharmaceutical treatment
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
GB9003543D0 (en) * 1990-02-16 1990-04-11 Wellcome Found Therapeutic nucleosides
DE69324244T2 (de) * 1992-01-06 1999-09-30 The Wellcome Foundation Ltd., Greenford Therapeutische nukleoside der 2',3'-dideoxy-3'-fluor -purin reihe
GB9200150D0 (en) * 1992-01-06 1992-02-26 Wellcome Found Therapeutic nucleosides
US5360714A (en) * 1992-08-28 1994-11-01 Fox Chase Cancer Center Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof
US5334525A (en) * 1992-08-28 1994-08-02 Fox Chase Cancer Center Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
ATE284894T1 (de) * 1994-10-24 2005-01-15 Genencor Int L-pyranosyl-nukleoside
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
TR200002273T2 (tr) * 1997-08-15 2002-06-21 Medivir Ab Hepatit B virüsü (HBV) retroviral ters transkriptaz ve DNA polimeraz inhibe edicilerini içeren antiviraller gibi nükleozidlerin analogları.
ATE314851T1 (de) * 2002-06-27 2006-02-15 Medivir Ab Synergistische wechselwirkung von abacavir und alovudin
EP1610797A1 (fr) * 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Combinaison antivirale de nevirapine et d'un autre compose antiretroviral
WO2004087140A1 (fr) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Combinaison antivirale d'une dipyridodiazepinone et compose antiretroviral
WO2004087139A1 (fr) 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Combinaison antivirale de tipranavir et d'un autre compose antiretroviral

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3775397A (en) * 1969-11-12 1973-11-27 Akad Wissenschaften Ddr Novel cytostatic 2',3'-dideoxy-3'-fluoropyrimidine-nucleosides
DD139793A1 (de) * 1978-11-06 1980-01-23 Waltraud Braun Mittel gegen psoriasis
DD158903A1 (de) * 1981-05-18 1983-02-09 Gotthard Kowollik Verfahren zur herstellung von 3'-fluor-2',3'-didesoxyadenosin
DD209197A1 (de) * 1981-07-21 1984-04-25 Akad Wissenschaften Ddr Verfahren zur herstellung von 3'-fluor-2',3'-didesoxyguanosin
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPH07116042B2 (ja) * 1985-05-15 1995-12-13 ザ ウエルカム フアウンデ−シヨン リミテツド ヌクレオシド化合物
EP0258412A1 (fr) 1986-02-20 1988-03-09 GREER, Sheldon B. Composition et procede de traitement du sida et de certaines maladies s'y rapportant

Also Published As

Publication number Publication date
US6358934B1 (en) 2002-03-19
JPH01500193A (ja) 1989-01-26
DK92788A (da) 1988-02-23
AU7700587A (en) 1988-01-29
DE3773892D1 (de) 1991-11-21
AU598575B2 (en) 1990-06-28
WO1988000050A1 (fr) 1988-01-14
SE8602981D0 (sv) 1986-07-04
DK92788D0 (da) 1988-02-23
JP2540576B2 (ja) 1996-10-02
ATE68349T1 (de) 1991-11-15
EP0277151A1 (fr) 1988-08-10
EP0277151B1 (fr) 1991-10-16
DK172617B1 (da) 1999-03-01

Similar Documents

Publication Publication Date Title
CA1286991C (fr) Medicament pour le traitement des infections a virus
JP2525418B2 (ja) 後天性免疫不全症ａｉｄｓに対する医薬
US4861759A (en) Antiviral compositions and methods
US4880782A (en) Method of treating viral infections in humans and compositions therefor
JP2001500471A (ja) プロテアーゼインヒビターの生物学的及び抗ウイルス活性を改善する方法
IE860677L (en) Antiviral formulation
US5446029A (en) Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
IE60866B1 (en) The use of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
US5215971A (en) Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
US5084445A (en) 3'-azido-2',3'-dideoxy-5-methylcytidine
US5616566A (en) Method of inhibiting HIV replication with 2',3'-dideoxyadenosine
EP0355825A2 (fr) Système du traitement viral
EP0294443B1 (fr) Utilisation de nucleosides pour la fabrication d'un medicament destine aux traitements de maladies causees par un retrovirus ou par le virus de l'hepatite b
Weis et al. L-ribofuranosyl nucleosides
JP3693357B2 (ja) 逆転写酵素阻害剤
IE903519A1 (en) Therapeutic nucleosides
US4093715A (en) 5-Iodo-5'-amino-2',5'-dideoxycytidine and the pharmaceutically acceptable salts thereof
EP0286825A2 (fr) Utilisation du 3'-fluro-3'-deoxythymidine pour fabriquer un médicament pour le traitement des infections virales
CA1092510A (fr) No translation available
EP0316592A2 (fr) 3'-Fluoro-2',3'-didéoxyuridine, et ses application thérapeutique
WO1988003804A2 (fr) Procede pour traiter des infections virales chez des humains, et compositions a cet effet
HU201678B (en) Process for producing pharmaceutical compositions against human retrovirus, comprising 3'-azido-3'-deoxythymide derivatives
CA1340519C (fr) Nucleosides antiviraux
AU644412B2 (en) 6-halo- and 2-amino-6-halo-purine 2',3'-dideoxy nucleosides and their use as antiviral agents
AU644412C (en) 6-halo- and 2-amino-6-halo-purine 2',3'-dideoxy nucleosides and their use as antiviral agents

Legal Events

Date Code Title Description
MKEX Expiry